Holman Reports 30,000‑Share Conversion After Domestication

Rhea-AI Filing Summary

Albert A. Holman III reported a non‑cash conversion of equity in connection with Helix Acquisition Corp. II's business combination and domestication that resulted in holdings in BridgeBio Oncology Therapeutics, Inc. [BBOT]. On 08/11/2025 Mr. Holman's 30,000 Class B ordinary shares were converted one‑for‑one into Helix Class A ordinary shares and then into 30,000 shares of the issuer's common stock at a price of $0 per share, leaving him with 30,000 shares beneficially owned in a direct ownership form. The filing also notes he resigned as a director of Helix effective the same date, immediately prior to the domestication.

This Form 4 documents a structural conversion tied to the closing of the business combination and domestication rather than an open‑market purchase or sale.

Positive

• 30,000 Class B ordinary shares converted one‑for‑one into 30,000 common shares, preserving the reporting person's economic stake
• Conversion occurred at $0, indicating a non‑cash structural conversion (transaction code M) rather than a sale
• Beneficial ownership after conversion is clearly reported as 30,000 shares (Direct)

Negative

• Reporting person resigned as a director of Helix effective 08/11/2025, immediately prior to the domestication

Insights

Financial Analyst

TL;DR: A non‑cash, one‑for‑one conversion preserved Mr. Holman's 30,000‑share stake; no sale or cash proceeds were reported.

The Form 4 shows a mechanical conversion of 30,000 Class B ordinary shares into 30,000 common shares as part of Helix's domestication and business combination, reported on 08/11/2025. The transaction code M and the $0 price indicate a conversion event rather than a market transaction. From an investor‑impact perspective, there is no immediate dilution or cash flow effect disclosed in this filing and the beneficial ownership after the conversion is explicitly reported as 30,000 shares (direct).

Corporate Governance Expert

TL;DR: The filing documents corporate reorganization activity and notes the reporting person's resignation as a director immediately before domestication.

This Form 4 ties the share conversion to corporate governance actions: Helix migrated and domesticated as a Delaware corporation and converted share classes one‑for‑one into the issuer's common stock. The document explicitly states that Mr. Holman resigned as a director of Helix effective 08/11/2025, immediately prior to the domestication. The filing records ownership post‑conversion as 30,000 direct shares, and contains no additional governance disclosures such as change in officer title, board composition details beyond the resignation, or planned sales.

Insider Trade Summary

30,000 shares exercised/converted

Mixed 2 txns

Insider Holman Albert A III

Role Insider

Type	Security	Shares	Price	Value
Exercise	Class B ordinary shares	30,000	$0.00	--
Exercise	Common Stock	30,000	$0.00	--

Holdings After Transaction: Class B ordinary shares — 0 shares (Direct); Common Stock — 30,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holman Albert A III

(Last) (First) (Middle)

C/O HELIX ACQUISITION CORP. II

200 CLARENDON STREET, 52ND FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former Director

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2025		M(1)		30,000	A	(1)	30,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Class B ordinary shares	(1)	08/11/2025		M(1)			30,000	(1)	(1)	Class A ordinary shares	30,000	$0	0	D

Explanation of Responses:

1. In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date.

Remarks:

The Reporting person was a director of Helix prior to the Domestication and resigned from such role effective as of August 11, 2025, immediately prior to the Domestication.

	/s/ Albert A. Holman III	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed by Albert A. Holman III report?

The Form 4 reports a non‑cash conversion on 08/11/2025 in which 30,000 Class B ordinary shares were converted one‑for‑one into 30,000 shares of the issuer's common stock (price $0) and shows 30,000 shares beneficially owned (Direct) following the conversion.

Which company and ticker does this Form 4 concern?

The filing concerns BridgeBio Oncology Therapeutics, Inc. [BBOT], arising from actions related to Helix Acquisition Corp. II's business combination and domestication.

What is the transaction code and what does it mean here?

The transaction is reported with code M, which in this filing denotes a reclassification or conversion of securities related to the business combination/domestication rather than an open‑market trade.

Did the reporting person sell any shares for cash?

No. The Form 4 shows a conversion at a price of $0 and records no cash sale or purchase.

Did the filing record any change in the reporting person's role?

Yes. The filing states the reporting person resigned as a director of Helix effective 08/11/2025, immediately prior to the domestication.